These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 692231)

  • 1. [Myasthenia gravis (1). Experimental myasthenia gravis--a tool for the study of the pathogenesis, diagnosis and treatment of myasthenia gravis].
    Heilbronn E
    Lakartidningen; 1978 Oct; 75(41):3663-4, 3669. PubMed ID: 692231
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ocular myasthenia: a diagnostic and management challenge--a review].
    Langmann A; Lindner S; Koch M; Diez J
    Klin Monbl Augenheilkd; 2004 Feb; 221(2):77-86. PubMed ID: 14986204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Myasthenia gravis (2). Antibodies against acetylcholinergic receptros in myasthenia gravis].
    Bergström K; Lefvert AK
    Lakartidningen; 1978 Oct; 75(41):3665-7. PubMed ID: 692232
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antibodies to acetylcholine receptor. Diagnosis and therapeutic interest in myasthenia gravis (author's transl)].
    de Crousaz G
    Ann Chir; 1980 Mar; 34(3):188-92. PubMed ID: 7369693
    [No Abstract]   [Full Text] [Related]  

  • 5. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma.
    Mygland A; Tysnes OB; Matre R; Volpe P; Aarli JA; Gilhus NE
    Ann Neurol; 1992 Oct; 32(4):589-91. PubMed ID: 1333745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia gravis: an example of receptor disease.
    Conti-Tronconi BM; Fumagalli G; Scotti A; Brigonzi A; Sher E; Morgutti M; Clementi F
    Adv Biochem Psychopharmacol; 1980; 21():473-88. PubMed ID: 7376974
    [No Abstract]   [Full Text] [Related]  

  • 7. Idiotypes and anti-idiotypes of human autoantibodies to the acetylcholine receptor in myasthenia gravis.
    Lefvert AK
    Monogr Allergy; 1987; 22():57-70. PubMed ID: 3325836
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose intravenous immunoglobulin in the management of myasthenia gravis.
    Bonaventura I; Ponseti J; Arnau E; Matias-Guiu J; Codina Puiggros A
    Arch Intern Med; 1987 Feb; 147(2):207, 211. PubMed ID: 3813729
    [No Abstract]   [Full Text] [Related]  

  • 9. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
    Zoda T; Yeh TM; Krolick KA
    J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short review of progress in experimental myasthenia gravis, bearing on the pathogenesis of myasthenia gravis.
    Heilbronn E
    Prog Brain Res; 1979; 49():459-63. PubMed ID: 390612
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical study of autoimmune diseases: recent trends--with special reference to progress in immunological tests and therapeutic methods. Organ-specific autoimmune diseases. 3) Myasthenia gravis].
    Arimori S
    Nihon Rinsho; 1988 Apr; 46(4):907-11. PubMed ID: 3404711
    [No Abstract]   [Full Text] [Related]  

  • 12. 'Seronegative' myasthenia gravis is no longer seronegative.
    Lindstrom J
    Brain; 2008 Jul; 131(Pt 7):1684-5. PubMed ID: 18558616
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of inter-animal cross-reaction of anti-acetylcholine receptor antibodies at the receptor-binding site as demonstrated by heterologous anti-idiotype antisera: implications for immunotherapy of myasthenia gravis.
    Barkas T; Simpson JA
    Clin Exp Immunol; 1982 Jan; 47(1):119-26. PubMed ID: 7094417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiidiotypic antibodies in the regulation of experimental autoimmune myasthenia gravis.
    Souroujon MC; Fuchs S
    Ann N Y Acad Sci; 1987; 505():676-82. PubMed ID: 3500670
    [No Abstract]   [Full Text] [Related]  

  • 15. In-line affinity chromatographic removal of specific antibody from rabbits with experimental myasthenia gravis as a prelude to immunotherapy.
    Hinman CL; Stevens-Truss R
    Immunopharmacol Immunotoxicol; 1998 May; 20(2):233-49. PubMed ID: 9653670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of myasthenia gravis as a disorder of acetylcholine receptors.
    Drachman DB; Pestronk A; Stanley EF
    Adv Cytopharmacol; 1979; 3():237-44. PubMed ID: 382787
    [No Abstract]   [Full Text] [Related]  

  • 17. [Acetylcholine receptor antibody titer, sensitivity to curare electromyogram and disease severity in myasthenia gravis].
    Chen SM
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Jun; 24(3):169-73, 189. PubMed ID: 1889330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis: a clinical review.
    Burke WJ
    Clin Exp Neurol; 1981; 17():1-14. PubMed ID: 7346191
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
    Caress JB; Hunt CH; Batish SD
    Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.